Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP-HRMB trial in clinically high-risk medulloblastoma
NL-OMON58714Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, thiotepa, carboplatin and etoposide in medulloblastoma (4 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Apr 2022; status: recruiting.
02
Drugs
cyclophosphamidethiotepacarboplatinetoposide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON58714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58714.